| Composition of Certain Financial Statement Captions |
|
|
|
|
|
|
|
|
|
|
|
|
| (In thousands) |
September 30,
2020 |
|
December 31,
2019 |
| Accounts receivable, net: |
|
|
|
| Accounts receivable |
$ |
243,540 |
|
|
$ |
136,551 |
|
| Less: allowance for credit losses |
(1,996) |
|
|
(1,934) |
|
|
$ |
241,544 |
|
|
$ |
134,617 |
|
| Inventories, net: |
|
|
|
| Consumable supplies |
$ |
72,518 |
|
|
$ |
23,005 |
|
| Finished products |
30,268 |
|
|
25,142 |
|
| Work in-process |
6,425 |
|
|
3,238 |
|
| Raw materials |
6,343 |
|
|
4,586 |
|
| Less: inventory reserve |
(3,681) |
|
|
(2,537) |
|
|
$ |
111,873 |
|
|
$ |
53,434 |
|
| Other current assets and prepaid expenses: |
|
|
|
| Taxes recoverable |
$ |
14,072 |
|
|
$ |
19,808 |
|
| Prepaid expenses |
9,435 |
|
|
8,147 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Prepaid insurance |
6,635 |
|
|
3,486 |
|
| Other receivables |
714 |
|
|
3,262 |
|
| Other |
7,542 |
|
|
15,839 |
|
|
$ |
38,398 |
|
|
$ |
50,542 |
|
| Intangible assets, net: |
|
|
|
| Customer relationships |
$ |
446,794 |
|
|
$ |
445,408 |
|
| Technologies |
296,429 |
|
|
296,246 |
|
| Trade names |
49,791 |
|
|
49,786 |
|
|
|
|
|
| Covenants not to compete |
16,326 |
|
|
16,318 |
|
| Licenses |
5,766 |
|
|
5,766 |
|
| Product registrations |
7,430 |
|
|
7,578 |
|
| Other |
6,296 |
|
|
6,094 |
|
| Less: accumulated amortization |
(342,414) |
|
|
(298,234) |
|
|
$ |
486,418 |
|
|
$ |
528,962 |
|
| Accrued expenses: |
|
|
|
| Inventory received but not invoiced |
$ |
84,768 |
|
|
$ |
13,751 |
|
| Commitments and Contingencies |
22,669 |
|
|
38,635 |
|
| Employee benefits |
37,671 |
|
|
33,671 |
|
| Contract liabilities |
14,099 |
|
|
19,196 |
|
| Clinical trials |
5,912 |
|
|
8,122 |
|
|
|
|
|
| Contingent consideration |
2,374 |
|
|
2,375 |
|
| Finance leases short-term |
2,343 |
|
|
2,743 |
|
|
|
|
|
| Professional fees |
5,340 |
|
|
1,333 |
|
|
|
|
|
|
|
|
|
| Other |
73,246 |
|
|
45,099 |
|
|
$ |
248,422 |
|
|
$ |
164,925 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| (In thousands) |
September 30,
2020 |
|
December 31,
2019 |
|
|
|
|
| Other long-term liabilities: |
|
|
|
|
|
|
|
| Line of credit (see Note) |
$ |
— |
|
|
$ |
44,749 |
|
| Contingent consideration |
8,643 |
|
|
7,308 |
|
|
|
|
|
| Mortgages and other debts payable |
4,010 |
|
|
3,906 |
|
| Finance leases long-term |
2,538 |
|
|
4,046 |
|
| Contract liabilities |
2,951 |
|
|
2,571 |
|
| Other |
26,889 |
|
|
25,224 |
|
|
$ |
45,031 |
|
|
$ |
87,804 |
|
Note: Our line of credit with JPMorgan Chase Bank, N.A. was fully repaid as of September 30, 2020.
|
| Changes in Goodwill |
The following table summarizes the changes in Goodwill by reporting unit during the nine months ended September 30, 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2020 |
| (In thousands) |
Balance at January 1 |
|
|
|
Foreign exchange and other |
|
Balance at September 30th |
| Pharmaceuticals |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rayaldee |
$ |
85,605 |
|
|
|
|
$ |
3,791 |
|
|
$ |
89,396 |
|
|
|
|
|
|
|
|
|
| OPKO Chile |
4,348 |
|
|
|
|
(272) |
|
|
4,076 |
|
| OPKO Biologics |
139,784 |
|
|
|
|
— |
|
|
139,784 |
|
| OPKO Health Europe |
7,394 |
|
|
|
|
336 |
|
|
7,730 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Diagnostics |
|
|
|
|
|
|
|
| BioReference |
434,809 |
|
|
|
|
— |
|
|
434,809 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
671,940 |
|
|
|
|
$ |
3,855 |
|
|
$ |
675,795 |
|
|